Picture loading failed.

Anti-ERBB3 therapeutic antibody (Pre-made Patritumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Patritumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-431-1mg 1mg 3090
GMP-Bios-ab-431-10mg 10mg 21890
GMP-Bios-ab-431-100mg 100mg 148000
GMP-Bios-ab-431-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-ERBB3 therapeutic antibody (Pre-made Patritumab biosimilar,Whole mAb)
INN Name Patritumab
TargetERBB3
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2011
Year Recommended2012
CompaniesAmgen;U3 Pharma;Daiichi Sankyo Company
Conditions Approvedna
Conditions ActiveNon-small cell lung cancer;Head and neck cancer;Breast cancer
Conditions DiscontinuedSolid tumours
Development Techna